Search Results for “research” – Page 276 – media

Leaf Healthcare touts reduced pressure injuries in Leaf wearable sensor study

Patient monitoring system developer Leaf Healthcare today released results from a study exploring the ability of its Leaf wearable patient sensor to prevent pressure injuries on acutely ill adults, touting that patients were 73% less likely to develop such injuries when monitored with the device.
- Source: Mass Device
- 612
- January 24, 2018
medical device Researches wearables
Biosimilar Avastin wins EU approval

European regulators have issued a green light for Amgen and Allergan’s Mvasi, marking the first biosimilar of Roche’s Avastin to be approved in the region. The drug has been cleared to treat a range of indications spanning carcinoma of the colon or rectum, breast cancer; nonsquamous non-small cell lung cancer, renal cell cancer; platinum-sensitive, or platinum-resistant recurrent epithelial ovarian, fallopian tube, or primary peritoneal cancer and cervical cancer. The companies noted that the approval came after trial data showed a high degree of similarity between Mvasi (biosimilar bevacizumab) and its reference drug, “with no clinically meaningful differences in terms of the efficacy, safety and immunogenicity between the products”. Mvasi is the first product borne out of an alliance between Amgen and Allergan to bag marketing authorisation from the European Commission, “highlighting the success of our joint commitment to developing cancer biosimilars,” noted David Nicholson, chief research and development officer at ...
- Source: Pharmatimes
- 567
- January 23, 2018
Avastin Mvasi New Approvals Roche
IoT devices vulnerable to Spectre and Meltdown exploitation

Healthcare organizations should use risk management processes to ensure the security of health information and protect against the vulnerabilities stemming from the Spectre and Meltdown threats.
- Source: Healthcare IT News
- 520
- January 23, 2018
healthcare technology Internet of Things Market Views medical device
Pandion Therapeutics Announces $58 Million Series A Financing to Advance Tissue-Specific Immune Modulator Drugs

Pandion Therapeutics, Inc., a biotechnology company developing bispecific antibody therapeutics to achieve localized immunomodulation, today announced the completion of a $58 million Series A financing. This funding will be used to advance its initial drug programs for autoimmune and inflammatory diseases toward the clinic, as well as to continue building the company’s technology platform and pipeline. Polaris Partners, the founding investor that provided the initial seed funding, co-led the Series A financing along with Versant Ventures and Roche Venture Fund. SR One and BioInnovation Capital also participated in the round.
- Source: finance.yahoo
- 898
- January 22, 2018
antibody Company Insight immunomodulation
Adlai Nortye Enters into Global Licensing Agreement with Eisai for EP4 Antagonist

Adlai Nortye Biopharma Co., Ltd. (NEEQ: 870946) ("Adlai Nortye" or "the Company"), a biopharmaceutical company dedicated to discovery and commercialization of new and effective drugs, announced today that it had entered into a Global Licensing Agreement ("the Agreement") with Eisai Co., Ltd. ("Eisai"), a global pharmaceutical company with a focus on serving patients with unmet medical needs.
- Source: Prnewswire
- 768
- January 22, 2018
biopharmaceutical EP4 antagonist Market Views
Creation of synthetic horsepox virus could lead to more effective smallpox vaccine

UAlberta researchers created a new synthetic virus that could lead to the development of a more effective vaccine against smallpox. The discovery demonstrates how techniques based on the use of synthetic DNA can be used to advance public health measures.
- Source: medicalxpress
- 675
- January 22, 2018
smallpox synthetic DNA synthetic virus vaccine
Modification of the Associations Between Duration of Oral Contraceptive Use and Ovarian, Endometrial, Breast, and Colorectal Cancers

Findings In this population-based cohort study of more than 100, 000 predominantly postmenopausal women, risk reductions for ovarian cancer associated with increasing duration of oral contraceptive use were generally consistent across health behaviors. For endometrial cancer, the reductions were strongest among current smokers, obese women, and those who exercised rarely; lack of associations with breast and colorectal cancer were consistent across health behaviors.
- Source: Jamanetwork
- 515
- January 22, 2018
cancer oral contraceptive use Researches
Functionality, usability cited as barriers to adoption of caregiver digital health tools in AARP report

In 2014, research by the AARP estimated that 40 million Americans provide unpaid care to an adult. About 68 percent of family caregivers have no paid help and by 2020, 45 million family caregivers will care for 117 million people, according to a new report on caregivers that is part of AARP’s Project Catalyst.
- Source: MedCity News
- 594
- January 22, 2018
healthcare Home medical equipment Researches
The Top 8 Technologies Combating Food Allergy

Food allergy has been referred to as the second wave of the allergy epidemic, asthma being the first.
- Source: Medical Futurist
- 929
- January 22, 2018
Allergies Company Insight digital health healthcare technology mHealth
Blood cancer care needs improving, finds MP inquiry

The Government’s 2015 Cancer Strategy is failing to support blood cancer patients in the UK and care must improve, an MP inquiry has found.
- Source: pharmatimes
- 649
- January 19, 2018
blood cancer NHS polices

your submission has already been received.

OK

Subscribe

Please enter a valid Email address！

Submit

The most relevant industry news & insight will be sent to you every two weeks.

more

more

Customer Services
Contact Us
Help Center

Buy on Drugdu.com
Browse Product Categories

Free APP

Follow Us

Terms & Conditions | Privacy Policy

粤ICP备16008861号

Copyright © 2016-2018 Drugdu.com. All Rights Reserved.